Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Maze Therapeutics

Maze Therapeutics Reports Positive First-in-Human Data From Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (AKD)
From Maze Therapeutics
Via Business Wire
Maze Therapeutics to Present New Data Supporting Advancement of MZE829 and MZE782 Clinical Development at American Society of Nephrology’s Kidney Week and American Society of Human Genetics Annual Meeting
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Initiates Phase 1 First-in-Human Trial Evaluating MZE782 as a Potential Treatment for Chronic Kidney Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics to Participate in Upcoming Investor Conferences
From Maze Therapeutics
Via Business Wire
Maze Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Highlights New Preclinical Data Supporting Advancement of APOL1 Inhibitor Candidate Toward Clinical Evaluation for APOL1 Kidney Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
From Maze Therapeutics
Via Business Wire
Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics to Present Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease at the WORLDSymposium 2023
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Appoints Harold Bernstein, M.D., Ph.D., as President, Research and Development and Chief Medical Officer
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Appoints Sekar Kathiresan, M.D., to its Board of Directors
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces Publication in Nature Describing a Novel Mechanism Linking Well-Established Genetic Drivers of ALS and FTD
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease
From Maze Therapeutics
Via Business Wire
Maze Therapeutics to Present Preclinical Data Highlighting MZE001 as a Potential Treatment for Pompe Disease at 2022 WORLD Symposium
From Maze Therapeutics
Via Business Wire
Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases
From Maze Therapeutics
Via Business Wire
Maze Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Maze Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.